Potent Sodium/Glucose Cotransporter SGLT1/2 Dual Inhibition Improves Glycemic Control Without Marked Gastrointestinal Adaptation or Colonic Microbiota Changes in Rodents

Fuyong Du, Simon A. Hinke, Alexandre Cavaunagh, David Polidori, Nathaniel Wallace, Thomas Kirchner, Matthew Jennis, Wensheng Lang, Gee-Hong Kuo, Micheal D. Gaul, James Lenhard, Keith Demarest, Nadim J. Ajami, Yin Liang, and Pamela J. Hornby

Cardiovascular and Metabolism Discovery (F.D., S.A.H., C.C., N.W., T.K., M.J., G.-H.K., M.D.G., J.L., K.D., Y.L., P.J.H.) and Analytical Sciences (W.L.), Janssen R&D LLC, Spring House, Pennsylvania; Cardiovascular and Metabolism Experimental and Translational Medicine, Janssen R&D LLC, San Diego, California (D.P.); and Alkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas (N.J.A.)

Received February 18, 2018; accepted March 22, 2018

The sodium/glucose cotransporters (SGLT1 and SGLT2) transport glucose across the intestinal brush border and kidney tubule. Dual SGLT1/2 inhibition could reduce hyperglycemia more than SGLT2-selective inhibition in patients with type 2 diabetes. However, questions remain about altered gastrointestinal (GI) luminal glucose and tolerability, and this was evaluated in slc5a1<sup>-/-</sup> mice or with a potent dual inhibitor (compound 8; SGLT1 <i>K<i>50</i> = 1.5 ± 0.5 nM 100-fold greater potency than phlorizin; SGLT2 <i>K<i>50</i> = 0.4 ± 0.2 nM). <sup>13</sup>C<sub>6</sub>-glucose uptake was quantified in slc5a1<sup>-/-</sup> mice and in isolated rat jejunum. Urinary glucose excretion (UGE), blood glucose (Sprague-Dawley rats), glucagon-like peptide 1 (GLP-1), and hemoglobin A1c (HbA1c) levels (Zucker diabetic fatty rats) were measured. Intestinal adaptation and rRNA gene sequencing was analyzed in C57BL/6 mice. The blood <sup>13</sup>C<sub>6</sub>-glucose area under the curve (AUC) was reduced in the absence of SGLT1 by 75% (245 ± 6 vs. 64 ± 6 mg/dl·h in wild-type vs. slc5a1<sup>-/-</sup> mice) and compound 8 inhibited its transport up to 50% in isolated rat jejunum. Compound 8 reduced glucose excursion more than SGLT2-selective inhibition (e.g., AUC = 129 ± 3 vs. 249 ± 5 mg/dl·h for 1 mg/kg compound 8 vs. dapagliflozin) with similar UGE but a lower renal glucose excretion threshold. In Zucker diabetic fatty rats, compound 8 decreased HbA1c and increased total GLP-1 without changes in jejunum SGLT1 expression, mucosal weight, or villus length. Overall, compound 8 (1 mg/kg for 6 days) did not increase cecal glucose concentrations or bacterial diversity in C57BL/6 mice. In conclusion, potent dual SGLT1/2 inhibition lowers blood glucose by reducing intestinal glucose absorption and the renal glucose threshold but minimally impacts the intestinal mucosa or luminal microbiota in chow-fed rodents.

Introduction

The sodium/glucose cotransporters SGLT1 and SGLT2 are driven by a sodium gradient created by Na<sup>+</sup>/K<sup>+</sup> ATPase. SGLT1 transports glucose into intestinal enterocytes, whereas SGLT2 (and to a lesser extent SGLT1) reabsorbs glucose in the kidney tubule. SGLT1 is located luminally on the small intestinal brush border in humans (Chen et al., 2010), rats (Balen et al., 2008), and mice (Yoshikawa et al., 2011), with negligible amounts elsewhere in the gastrointestinal (GI) tract. Glutamine is the primary energy source for enterocytes (Frankel et al., 1993) and glucose transporter 2 (GLUT2) transports most glucose basolaterally. Selective SGLT2 inhibitors, marketed for type 2 diabetes mellitus (T2DM), have varying selectivity for SGLT2 relative to SGLT1; for example, canagliflozin has some SGLT1 activity (SGLT2 IC<sub>50</sub> = 4.2 nM, SGLT1 IC<sub>50</sub> = 663 nM) (Mudaliar et al., 2015). Consistent with this in humans, the small intestinal brush border has similar <sup>13</sup>C<sub>6</sub>-glucose uptake was quantified in slc5a1<sup>-/-</sup> mice and compound 8 inhibited its transport up to 50% in isolated rat jejunum. Compound 8 reduced glucose excursion more than SGLT2-selective inhibition (e.g., AUC = 129 ± 3 vs. 249 ± 5 mg/dl·h for 1 mg/kg compound 8 vs. dapagliflozin) with similar UGE but a lower renal glucose excretion threshold. In Zucker diabetic fatty rats, compound 8 decreased HbA1c and increased total GLP-1 without changes in jejunum SGLT1 expression, mucosal weight, or villus length. Overall, compound 8 (1 mg/kg for 6 days) did not increase cecal glucose concentrations or bacterial diversity in C57BL/6 mice. In conclusion, potent dual SGLT1/2 inhibition lowers blood glucose by reducing intestinal glucose absorption and the renal glucose threshold but minimally impacts the intestinal mucosa or luminal microbiota in chow-fed rodents.

The sodium/glucose cotransporters (SGLT1 and SGLT2) transport glucose across the intestinal brush border and kidney tubule. Dual SGLT1/2 inhibition could reduce hyperglycemia more than SGLT2-selective inhibition in patients with type 2 diabetes. However, questions remain about altered gastrointestinal (GI) luminal glucose and tolerability, and this was evaluated in slc5a1<sup>-/-</sup> mice or with a potent dual inhibitor (compound 8; SGLT1 <i>K<i>50</i> = 1.5 ± 0.5 nM 100-fold greater potency than phlorizin; SGLT2 <i>K<i>50</i> = 0.4 ± 0.2 nM). <sup>13</sup>C<sub>6</sub>-glucose uptake was quantified in slc5a1<sup>-/-</sup> mice and in isolated rat jejunum. Urinary glucose excretion (UGE), blood glucose (Sprague-Dawley rats), glucagon-like peptide 1 (GLP-1), and hemoglobin A1c (HbA1c) levels (Zucker diabetic fatty rats) were measured. Intestinal adaptation and rRNA gene sequencing was analyzed in C57BL/6 mice. The blood <sup>13</sup>C<sub>6</sub>-glucose area under the curve (AUC) was reduced in the absence of SGLT1 by 75% (245 ± 6 vs. 64 ± 6 mg/dl·h in wild-type vs. slc5a1<sup>-/-</sup> mice) and compound 8 inhibited its transport up to 50% in isolated rat jejunum. Compound 8 reduced glucose excursion more than SGLT2-selective inhibition (e.g., AUC = 129 ± 3 vs. 249 ± 5 mg/dl·h for 1 mg/kg compound 8 vs. dapagliflozin) with similar UGE but a lower renal glucose excretion threshold. In Zucker diabetic fatty rats, compound 8 decreased HbA1c and increased total GLP-1 without changes in jejunum SGLT1 expression, mucosal weight, or villus length. Overall, compound 8 (1 mg/kg for 6 days) did not increase cecal glucose concentrations or bacterial diversity in C57BL/6 mice. In conclusion, potent dual SGLT1/2 inhibition lowers blood glucose by reducing intestinal glucose absorption and the renal glucose threshold but minimally impacts the intestinal mucosa or luminal microbiota in chow-fed rodents.

The investigators who are employees of Janssen R&D LLC and Baylor College of Medicine have no other conflict of interest to disclose.

ABBREVIATIONS: AUC, area under the curve; FITC, fluorescein isothiocyanate; GFR, glomerular filtration rate; GLP-1, glucagon-like peptide 1; GLUT, glucose transporter; GSK-1614235, 3-[[3-(4-((5-isopropyl-3-((23S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-1(4-pyrazol-4-y1)methyl]-3-methylphenoxo)propyl)amino]-2,2-dimethylpropanamide; HbA1c, hemoglobin A1c; HFD, high-fat diet; KGA-2727, 3-(4-[4-[[3-[[3-(3-chloro-4-(4-ethoxyphenyl)methyl]-3-methylphenoxy)propylamino]propionamide; KRB, Krebs-Ringer bicarbonate; LC, liquid chromatography; LX2761, (2R,3S,4R,5R)-3-(1-((2-(dimethylamino)ethyl)methyl)-3-methylphenoxy)-3-methyl-2-oxo-4-phenyl-5-oxo-2H-pyran-2-yl)benzylphenyl)-butanamide; LX4211, (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-ethoxyphenyl]methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol; MS, mass spectrometry; oGTT, oral glucose tolerance test; OTU, operational taxonomic unit; PCR, polymerase chain reaction; RT<sub>G</sub>, renal threshold for glucose; SCFA, short-chain fatty acid; SD, Sprague-Dawley; SDI, Shannon diversity index; SGLT, sodium/glucose cotransporter; T2DM, type 2 diabetes mellitus; UGE, urinary glucose excretion; WT, wild type; ZDF, Zucker diabetic fatty.
transient inhibition of intestinal SGLT1 occurs with 300 mg canagliflozin (Polidori et al., 2013b). In clinical testing, a dual SGLT1/2 inhibitor, sitagliptin/linagliptin/LX4211 ([2S,3R,4R,5S,6R]-2-[4-chloro-3-[[4-ethoxyphenyl]methyl]phenyl]-6-methylsulfonyloxane-3,4,5-triol) (SGLT2 IC50 = 1.8 nM, SGLT1 IC50 = 50 nM), also delayed glucose uptake after an oral glucose or meal test and increased systemic levels of glucagon-like peptide 1 (GLP-1) and peptide YY (Zambrowicz et al., 2012, 2013a). The delay in and augmentation of GLP-1 occurs elevated in DPP4-deficient rats (Oguma et al., 2016). The effect of canagliflozin on GLP-1 is enhanced in DPP4-deficient rats (Oguma et al., 2016). The SGLT1-selective inhibitor, GSK-1614235 [3-((3-(4-[[3-(methylphenoxy)propyl]amino]-2,2-dimethylpropanamide, H tetrahydro-2 nM, SGLT1 IC50 phenyl]-6-methylsulfanyloxane-3,4,5-triol] (SGLT2 IC50 propyl-3-(((2 SGLT1-selective inhibitor, GSK-1614235 [3-((3-(4-((5-isoo-}

**Materials and Methods**

**Animals.** All reported studies on rats and mice were carried out in accordance with the recommendations in the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The protocols for all studies performed at Janssen Pharmaceuticals were approved by the Johnson & Johnson Animal Care and Use Committee. Age-matched C57Bl/6 wild-type (WT) mice and fully back-crossed mice lacking one allele (heterozygous) or both alleles (homozygous null) of Sglt1 (slc5a1) were obtained from Taconic Biosciences (Hudson, NY) at age 20–22 weeks. Mice were singly housed and fed a 60% high-fat, low-carbohydrate diet ad libitum (D12492, Research Diets, New Brunswick, NJ). Male Sprague-Dawley (SD) rats were obtained from Charles River Laboratories International (Wilmington, MA) at age 7 to 8 weeks and fed a chow diet (Chow Diet 5K75; Research Diets). Male Zucker diabetic fatty (ZDF) rats were obtained from Charles River Laboratories at age 12 to 13 weeks and fed a chow diet (Formulab Diet 5008; Research Diets). All mice and rats (two per cage) were maintained in a temperature-controlled environment with a 12-hour/12-hour light/dark cycle (lights off, 1800; lights on, 0600) and had free access to water and food.

Blood glucose levels were measured using One-Touch glucometers (LifeScan Inc., Chesterbrook, PA) via a tail snip. Urine glucose levels were determined by the Olympus system with Genzyme diagnostics assay reagent (Sekisui Diagnostics, Lexington, MA). 13C6-glucose levels were determined using liquid chromatography (LC)–tandem mass spectrometry (MS) combined with dried blood spot sampling technology (Lang et al., 2014). Blood hemoglobin A1c (HbA1c) levels were tested using a Siemens DCA Vantage analyzer (Siemens, Munich, Germany). Plasma insulin and total GLP-1 concentrations were detected using electrochemiluminescent immunoassays (Meso Scale Discovery, Rockville, MD).

**SGLT1 Genotype Mouse Studies.** Oral glucose tolerance tests (oGTTS) were performed on conscious, unrestrained mice. Blood glucose levels of mice fasted overnight were measured, and the mice then received 2 g/kg [13C6-glucose (Cambridge Isotope Laboratories, Andover, MA) and glucose (1:1 ratio) by oral gavage. Blood levels of glucose and [13C6-glucose were measured at 0, 10, 30, 60, 120, 180, and 240 minutes after mice were given the [13C6-glucose challenge. Insulin tolerance tests were performed using human insulin (Humulin R; Eli Lilly, Indianapolis, IN). After 4-hour food removal, body weight and baseline blood glucose levels were measured and then insulin (0.75 U/kg s.c.) was injected and blood glucose levels were measured at 0, 15, 30, 60, and 120 minutes.

RNA was purified from mouse mucosa tissue utilizing the RNeasy Mini Kit (Qiagen, Hilden, Germany). In brief, tissues were homogenized in 500 μl lysis buffer with 5-mM-diameter sterile steel ball bearings in a tissue lyser (TissueLyser Ly2; Qiagen) for 4 minutes at 30 Hz. Homogenates were spun down at 12,000 rpm for 2 minutes at 4°C, and RNA was purified from supernatants according to the RNeasy protocol, utilizing the on-column DNase digestion additional quality control procedure (Qiagen). cDNA was generated by reverse transcription using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher, Waltham, MA) according to the manufacturer's protocols. qRT–polymerase chain reaction (PCR) was conducted using the via-7 real-time PCR machine and SYBR Green Master Mix (Thermo Fisher). Primer sequences were as follows: SLC5A1 (forward, 5'-CCCTCGTGGACTGCTATGC-3'); reverse, 5'-ATCAGCTTTGGGACTCATCC-3'); SLC2A2 (forward, 5'-CTCTCTGGTCCAGGTTGG-3'); reverse, 5'-ATCAAGAGGGCCTCAGTCAA-3'); SLC2A1 (forward, 5'-GTACTGTCGCGCGTTCTTG-3'); reverse, 5'-TACCCGGGGAGCCTTTTCT-3'); and glyceraldehyde-3-phosphate dehydrogenase (forward, 5'-GACTGGTAAAGGAGGCCG-3'; reverse, 5'-TACGGGAAATATGCGTCA-3'). The run method for qRT-PCR analysis consisted of the following: 1) hold state: 50°C for 2 minutes, 95°C for 3 minutes; 2) PCR stage: 95°C for 15 seconds, 60°C for 20 seconds, and 72°C for 30 seconds; and 3) melt curve for primer quality control. Results are represented by the fold change (where fold change equals 2^−ΔΔCT).
Glyceraldehyde-3-phosphate dehydrogenase served as the housekeeping control gene.

**SD Rat Studies.** For Ussing-type flux chamber experiments with isolated jejunal segment, fed rats were euthanized using CO₂ and the middle one-third of the small intestine (jejenum) was resected and washed with ice-cold Krebs-Ringer bicarbonate (KRB) buffer aerated with 95% O₂–5% CO₂. A 2-cm segment of rat jejunum was cut and placed onto a knitting needle (no. 9). Excess fat was removed and the outer intestinal muscle layer was scored using Dumont forceps. Cotton swabs were used to push away the serosal muscle layer so that it rolled over the mucosal layer, allowing it to then be removed. The mucosal layer was gently pulled off the knitting needle into ice-cold KRB buffer and opened longitudinally and then positioned in a cassette cartridge, which had an exposed a surface area of 0.1 cm² of the intestine. The cassette was placed into the chambers dividing the mucosal/apical sides from the serosal/basolateral sides. The apical chamber contained a modified KRB buffer recipe, which included 12.8 mM C-13-D-glucose rather than the typical 12.8 mM D-glucose. Basolateral side buffer samples C-13-D-glucose concentrations were quantified using Nimbuss LC-MS against internal standards (chromatographic description: LC-20AD pumps with an SII-20AC autosampler (Shimadzu, Kyoto, Japan); MS description: MDS Sciex API 5000 with an APCI source (Applied Biosystems, Foster City, CA)).

Fluorescein isothiocyanate (FITC)-dextran (Sigma, St. Louis, MO) was used to determine intestinal tissue integrity. FITC-dextran was added to the serosal/basolateral KRB buffer at a final concentration of 20 μg/ml. Relative fluorescence units were measured on a Safire² plate reader with an excitation wavelength of 492 nm (slit width = 10.0 nm) and an emission wavelength of 525 nm (slit width = 10.0 nm). Compound 8 in vitro potency (0.001 nM) and an emission wavelength of 525 nm (slit width = 10.0 nm).

**Rate of UGE**

This equation, along with measured values of UGE and blood glucose (BG) over each urine collection interval, and estimated GFR values were used to calculate RTG. Because even untreated, normoglycemic animals tend to have trace amounts of UGE, values of RTG were only calculated when UGE was at least 20 mg. The 24-hour mean RTG values were calculated as the weighted mean of the values obtained over each urine collection interval. In several cases, SD rats treated with compounds had a measured UGE greater than the calculated filtered glucose load (which is GFR × BG). In these cases, RTG was set to 0, which assumed no renal glucose reabsorption occurred (consistent with the measured UGE being even greater than the filtered glucose load). In vehicle-treated SD rats (and some SD rats treated with low doses of SGLT inhibitors), virtually no UGE was observed. In these rats, a value of 225 mg/dl was imputed based on (unpublished) data obtained with glucose infusion studies.

For subcutaneous administration of compound 8, the vehicle was 10% PEG-400/10% Solutol (n = 4) and rats were euthanized at 1 and 6 hours. To calculate the tissue/plasma ratio, routine LC-MS was used to detect compound 8 in the tissue (kidney and intestinal luminal contents, mucosal scraping, and serosa) and plasma.

**ZDF Rat Studies.** Male ZDF rats (aged 12–14 weeks) had blood glucose levels that were ≥350 mg/dl at the start of approximately 3 weeks of treatment while they were maintained on a reverse light cycle. On day 1, ZDF rats were allocated to different treatment groups based on their body weights and baseline fed blood glucose levels. Then animals were orally dosed with vehicle or compound 8 every day for 18 days. Fed blood glucose, body weights, and food weights were measured every 4 days. On day 15 blood HbA1c levels were measured. Blood glucose levels were measured at 0, 30, 60, and 120 minutes after oGTTs at 30 minutes and 6 hours after treatment. Oral or subcutaneous with vehicle (0.5% HPMC) or compounds expressing SGLT1 or SGLT2, as reported (Kuo et al., 2018).

**SGL1 Inhibition of Large Intestine Glucose in Mice and 16s rRNA Analysis.** Male C57Bl/6 mice were dosed with 1 mg/kg compound 8 for 5 days in the late afternoon prior to the dark cycle and were fed regular chow or high-sucrose (35%) diets. Control mice were fed regular chow and dosed with vehicle. Body weight, fasted (4-hour) blood glucose, fed blood glucose, gross cecal weight, and cecal glucose content were measured. At harvest on day 6, the cecum was ligated at the ileocecal junction and the entire weight including contents was recorded for calculation of the percentage of cecal weight to body weight. Cecal contents were diluted 1:1 with 0.9% NaCl and placed on wet ice and vortexed 1500g at 4°C for 10 minutes, and the supernatant sample was used for glucose analysis by an Autokit Glucose kit (Wako, Osaka, Japan) using a SpectraMax Plus384 plate reader (Molecular Devices). In addition to comparing cecal bacterial composition at harvest, fecal bacterial diversity was assessed in fecal pellets collected at days 0, 2, and 5 and understood dynamic changes. All cecal and fecal samples (72 samples total) were shipped to Diversigen Inc. (Houston, TX) for 16s rRNA gene sequencing, which included extraction, PCR amplification, sequencing (MiSeq; 2 × 250 bp; Illumina, San Diego, CA), and analysis (Caporaso et al., 2011, 2012). Mouse cecal contents and fecal pellet sequencing identified 235 operational taxonomic units (OTUs) with a cutoff of 4074 reads/sample. All samples were included in the analysis of bacterial richness, diversity, and taxonomic relative abundance.

All statistical analysis was performed by parametric t tests or analysis of variance with Bonferroni, Tukey, or Dunnett multiple comparisons post hoc tests (GraphPad Prism, version 7.0; Graph Pad Software Inc., La Jolla, CA). Statistical significance was defined as P < 0.05. A Kruskal-Wallis nonparametric analysis of variance was used to analyze terminal insulin levels in slc5a1−/− mice, due to high variability without normal distribution.

**Results Was Done**

Glucose homeostasis was assessed in genetically modified slc5a1 homoygous null (slc5a1−/−) or heterozygous (slc5a1+/−) mice and compared with age-matched WT c57 control mice.
Ileal and jejunal mucosa isolated from WT mice had robust expression of slc5a1 mRNA that was essentially absent in slc5a1^{-/-} mice and intermediate between those in slc5a1^{+/−} mice (Fig. 1A) that had been fed a high-fat diet (HFD). GLUT2 mRNA expression was similar in all groups, consistent with normal facilitated transport of absorbed glucose (data not shown). An oGTT ([13C]-glucose/glucose 1:1) resulted in a glucose excursion as measured by glucometer that was markedly lower in slc5a1^{-/-} mice compared with WT and heterozygous mice (Fig. 1B). Detection of [13C]-glucose for absorbed glucose (Fig. 1C) illustrated that the peak levels were reduced to <25% of slc5a1^{+/−} and WT peak levels in slc5a1^{-/-} mice. This difference was reflected in the area under the curve (AUC) for [13C]-glucose, which was approximately 25% of WT in slc5a1^{-/-} mice (Fig. 1D). Consistent with these glucose levels, terminal insulin levels in slc5a1^{-/-} mice were low compared with WT and slc5a1^{+/−} mice (Fig. 1E). An increase in endogenous SGLT1 expression has been reported in obesity;

**Fig. 1.** Glucose homeostasis and slc5a1 mRNA in slc5a1^{-/-}, slc5a1^{+/−}, and WT mice. (A) slc5a1 mRNA levels in jejunal (cross-hatched bars) and ileal (horizontal bars) mucosa were low in homozygous slc5a1^{-/-} mice and intermediate in slc5a1^{+/−} mice compared with WT (n = 7 to 8/group). *P < 0.05 (compared with WT); †P < 0.05 (compared with slc5a1^{+/−}). (B) Glucose excursion after an oGTT (50% [13C]-glucose and 50% glucose) in slc5a1^{-/-} mice (squares) was markedly lower than in WT (circles) and heterozygous mice (triangles). (C) Blood [13C]-glucose excursions were similar to glucose, but with a better separation among the three animal models. (D) Blood glucose AUC in the same mice. *P < 0.05 (compared with WT; black bar); †P < 0.05 (slc5a1^{+/−} compared with slc5a1^{-/-} mice; gray bar and white bar, respectively). (E) Terminal plasma insulin levels in the same mice, showing that insulin was lower in slc5a1^{-/-} mice than both WT (*P < 0.05) and slc5a1^{+/−} mice (†P < 0.05 by Kruskal-Wallis nonparametric analysis of variance due to high variability. (F) Jejunal mucosa slc5a1 expression in HFD-fed DIO mice (cross-hatched bars) was not consistently changed relative to lean chow-fed WT mice (stippled bars) in three separate experiments (n = 7 to 8/group). GAPDH, glyceraldehyde-3-phosphate dehydrogenase; DIO, diet-induced obese.
therefore, we assessed jejunum slc5a1 mRNA expression in diet-induced obese C57Bl/6 WT mice. However, different results were obtained in three repeat experiments of no change, upregulation, and downregulation in slc5a1 mRNA expression in diet-induced obese mice relative to lean controls (Fig. 1F).

Endogenous SGLT1 engagement was assessed by $^{13}$C$_6$-glucose transit across isolated muscle-stripped jejunum in Ussing-type flux chambers using dual SGLT1/2 inhibitor compound 8 (Kuo et al., 2018). Tissue integrity of the jejunal mucosa, as measured by FITC-dextran detection on the basolateral side after apical administration, was acceptable and stable over time in the presence of dimethylsulfoxide with or without compound 8 (Fig. 2A). Thus, in subsequent experiments, FITC-dextran detection of >150 relative fluorescence units after 90-minute incubation was discarded from $^{13}$C-glucose analysis. Compound 8 (1 μM) reduced the uptake of apically applied $^{13}$C-glucose over time compared with dimethylsulfoxide vehicle alone (Fig. 2B). At 90 minutes, compound 8 (1 and 10 μM) inhibited $^{13}$C-glucose detection on the basolateral side relative to vehicle but did not completely abolish it even at 10 μM (Fig. 2C).

In SD rats, compound 8 (0.1–10 mg/kg p.o.) given 30 minutes prior to an oGTT reduced glucose excursion (Fig. 3A), glucose AUC (Fig. 3C), and UGE (Fig. 3E). Blood glucose levels were significantly reduced by all doses of compound 8 and the three highest doses of a potent SGLT2-selective inhibitor, dapagliflozin (Fig. 3, B and D). Furthermore, UGE at 0–24 hours was comparable for both compound 8 (Fig. 3E) and dapagliflozin (Fig. 3F), although blood glucose levels were lower with compound 8 than with dapagliflozin. As a result, the mean RT$_G$ values were lower for compound 8 (Fig. 3G) than for dapagliflozin (Fig. 3H); at the highest doses of compound 8, complete inhibition of renal glucose reabsorption was achieved, as evidenced by RT$_G$ values of approximately 0.

Subcutaneous (instead of oral) administration of compound 8 (0.3 and 10.0 mg/kg) increased UGE 0–4 hours after dosing 30 minutes prior to an oGTT, reduced glucagon (Fig. 4A), and prevented the postprandial blood glucose excursion (Fig. 4, B and C) in a similar fashion to oral administration. At termination, 6 hours after subcutaneous dosing, plasma levels were low for both doses of compound 8 (0.06 ± 0.03 and 0.07 ± 0.00 μM). The tissue/plasma ratio was elevated in the kidney and in the small intestinal, but not colonic, mucosa (Fig. 4D). The ratio of compound 8 levels in small intestinal luminal content to plasma was low, but the colonic luminal contents had an elevated ratio, which could arise from sloughed off intestinal enterocytes containing compound 8. Combined, these data suggest that compound 8 rapidly reaches SGLT1 in the small intestinal brush border after parenteral administration.

In ZDF rats, compound 8 (0.3 and 1.0 mg/kg p.o. for 15 days) reduced fed blood glucose (Fig. 5A), the AUC of an oGTT (Fig. 5B), and circulating HbA1c levels (Fig. 5C) compared with vehicle. At the same time, the higher dose increased total circulating GLP-1 (Fig. 5D) and body weight gain (Fig. 5E), whereas food intake remained the same over the entire study (data not shown). At 3 weeks, animals euthanized at 24 hours after the last dose of compound 8 had plasma levels below the level of quantification; however, detectable levels were noted in the small intestine and
kidney at both the 0.3 (data not shown) and 1.0 mg/kg doses (Fig. 5F). In the jejunum mucosa of these rats, there was no difference in the level of expression of mRNA encoding SGLT1, GLUT1, or GLUT2 mRNA after dosing with compound 8 compared with vehicle (Fig. 5G). Consistent with this, jejunum brush border membrane SGLT1

Fig. 3. (A–H) SGLT1/2 dual inhibition (compound 8; A, C, E, and G) and SGLT2-selective inhibition (dapagliflozin; B, D, F, and H) dosed orally in SD rats reduced glucose excursion after oGTT and increased UGE. (A and B) Blood glucose excursions (0.1–10 mg/kg compound 8 or dapagliflozin given 30 minutes prior) were reduced in a dose-related manner compared with vehicle. (C and D) Glucose AUC during the oGTT was significantly reduced by all doses of compound 8 and the three highest doses of dapagliflozin. (E and F) Comparable increase in UGE over 0–24 hours for both compound 8 and dapagliflozin at 1–10 mg/kg. (G and H) During the same time, mean RTG values were lower for compound 8 than dapagliflozin and complete inhibition of renal glucose was achieved at the highest doses of compound 8. * = P < 0.05 by analysis of variance or the Tukey or Dunnett multiple comparisons test.
immunostaining was qualitatively similar in all groups (n = 4/group). Representative digital images illustrate that approximately 90% of the brush border had moderate to strong SGLT1 expression across all groups (Fig. 5H). There was no apparent small intestinal mucosal adaptation, since the gross jejunum mucosal weight of a 2-cm segment was similar in all groups (0.19 ± 0.02, 0.19 ± 0.01, and 0.23 ± 0.02 g for vehicle, 0.3 mg/kg, and 1.0 mg/kg, respectively; n = 4–8/group). Morphometric analysis (n = 4/group) confirmed that there was no difference in the villus/crypt ratio or villus length (671 ± 36, 496 ± 20, and 651 ± 18 μm for vehicle, 0.3 mg/kg, and 1.0 mg/kg, respectively). There was no difference in cecal content glucose concentration (23.3 ± 7.5, 29.2 ± 5.1, and 26.8 ± 3.6 mg/dl for vehicle, 0.3 mg/kg, and 1.0 mg/kg, respectively; n = 8/group) or pH (6.3 ± 0.1, 6.3 ± 0.1, and 6.4 ± 0.1 for vehicle, 0.3 mg/kg, and 1.0 mg/kg, respectively; n = 8/group).

Mice were fed chow or a high-sucrose diet combined with compound 8 (1 mg/kg p.o. for 6 days). At termination, gross cecal weight was decreased in mice fed a high-sucrose diet and treated with compound 8 (Fig. 6A) but overall the cecal glucose concentration was similar (Fig. 6B). There was no difference in body weight or fed blood glucose levels (data not shown) and fecal pellet consistency and wet weight were similar in all groups (data not shown). Although cecal glucose was not different, there was an increase in variability in chow-fed mice treated with compound 8. However, when we compared cecal bacterial diversity, as measured by the number of observed OTUs, there was no correlation with cecal glucose concentration in the same mice as shown by 16S rRNA gene sequencing (Fig. 6C). At termination, the relative abundance of certain phyla represented in cecal contents only differed in mice fed a high-sucrose diet with compound 8. In these mice, higher Bacteroidetes and lower Firmicutes were represented compared with mice fed chow with compound 8 or mice fed chow plus vehicle (Fig. 6D). Cecal and fecal sample microbial diversity, collected at the termination of the study, was highly correlated, as measured by the Shannon diversity index (SDI; Fig. 6E). Longitudinal analysis alone of fecal SDI changed on day 2 after mice were switched to a high-sucrose diet with compound 8 and this diversity was maintained to day 6 (Fig. 6F), whereas the addition of compound 8 or vehicle in chow-fed mice was not different throughout the study. The relative abundance of bacterial orders, as well as bacteria of interest in metabolic disease (e.g., Akkermansia spp.), was not altered by compound 8 (data not shown).
Fig. 5. SGLT1/2 inhibitor compound 8 given chronically to ZDF rats improved indices of hyperglycemia. (A) Compound 8 (squares, 0.3 mg/kg; triangles, 1.0 mg/kg) decreased fed blood glucose in a dose-related manner from day 0 to day 15 compared with elevated levels in vehicle-treated (circles). (B and C) On day 15, both doses (light and dark gray bars) compared with vehicle (white bar) decreased the AUC of glucose excursion after an oGTT after compound 8 was dosed 1 hour earlier (B) and reduced circulating HbA1c (C). (D and E) The higher dose of compound 8 increased total GLP-1 (D) and the gain in body weight at day 15 compared with vehicle (E). *P < 0.05 (both doses compared with vehicle-treated mice); †P < 0.05 (1.0 mg/kg dose compared with vehicle-treated mice); ‡P < 0.05 (1.0 mg/kg compared with 0.3 mg/kg treated rats by one-way or two-way analysis of variance). (F) Twenty-four hours after compound 8 administration (1 mg/kg), tissue levels were detected in intestinal mucosa and serosa/muscularis, as well as kidney. Bars indicate the following: white, intestinal luminal contents; stippled, mucosa; filled, serosa/muscularis externa; and hashed, kidney. (G) No effect of compound 8 (0.3 and 1.0 mg/kg) relative to vehicle-treated jejunal mucosa mRNA levels encoding SGLT1 (slc5a1; black bar), GLUT1 (slc2a1; white bar), or GLUT2 (slc2a2; gray bar). (H) Representative digital images of SGLT1 immunohistochemical staining in brush border membrane. Scale bar, 100 μm.
**Discussion**

The key findings are that potent SGLT1/2 dual inhibition by compound 8, more so than SGLT2-selective inhibition by dapagliflozin, reduced the oGTT glucose excursion and renal glucose thresholds. When given chronically to ZDF rats, compound 8 reduced HbA1c levels with increased circulating total GLP-1 as expected through intestinal mechanisms. This was not associated with obvious small intestinal adaptation, such as mucosal growth or villus length, or with compensatory changes in SGLT1 expression. In vivo compound 8 did not elevate colonic luminal glucose levels overall, potentially a consequence of small intestinal glucose “escaping” to the colon. Colonic glucose levels were not associated with altered bacterial population changes during the time frame studied, although there was an impact on the Firmicutes/Bacteroidetes ratio when compound 8 was combined with a high-sucrose diet. These points will be discussed in the context of the literature.

Glucose absorption from the small intestine could not be completely abolished in either slc5a1<sup>-/-</sup> mice or after compound 8 treatment. Loss of expression was confirmed in jejunal mucosa from slc5a1<sup>-/-</sup> mice and intermediate between WT and slc5a1<sup>-/-</sup> in slc5a1<sup>-/-</sup> mice. Mice had similar baseline blood...
glucose levels but after an oGTT, the resulting 13C-glucose excursion was about 25% of WT levels. Interestingly, there was no genetic “titration” of glucose uptake in heterozygous mice, which had similar 13C-glucose uptake to WT mice. Paracellular uptake of glucose occurs by solvent drag through intercellular junctions that are dilated by perijunctional contractile proteins during fluid absorption induced by Na+ -coupled transport (Pappenheimer and Reiss, 1987; Nuñez et al., 2000). In isolated rat jejunal mucosa, compound 8 demonstrated functional SGLT1 inhibition by the reduction in glucose uptake, but only to a maximal 50% reduction. This is likely due to the absence of blood circulation, which helps provide the gradient for paracellular absorption during a high nutrient load that would otherwise overwhelm the SGLT1 V\text{max}. Terminal insulin levels in slc5a1−/− mice were low compared with WT mice. However, slc5a1−/− mice respond to oral glucose with increased circulating GLP-1 (Powell et al., 2013a), suggesting that fermentation to SCFA enhances GLP-1 release in these mice.

In rats given compound 8, postchallenge glucose excursion was reduced similar to a related SGLT1/2 inhibitor, compound 19 (Kuo et al., 2018). At higher doses, postchallenge blood glucose levels were reduced below baseline and to a greater extent than SGLT2-selective inhibitor dapagliflozin. This is presumably due to the reduction in glucose uptake combined with a reduced renal threshold for UGE. Whether this would translate to a risk for hypoglycemia in patients is unclear. In a phase III trial of patients with type 1 diabetes mellitus (ClinicalTrials.gov identifier NCT02531035), dual selective LX4211/sotagliflozin achieved HbA1c <7.0 at week 24 but rates of diabetic ketoacidosis were higher than with placebo (Garg et al., 2017). Documented hypoglycemia (blood glucose ≤70 mg/dl) was similar for the sotagliflozin and placebo groups, and only three patients (two in the sotagliflozin group and one in the placebo group) discontinued the treatment due to severe hypoglycemia (Garg et al., 2017).

Both compound 8 and SGLT2-selective dapagliflozin evoked similar UGE in SD rats, but blood glucose levels were lower for compound 8. Compound 8 achieved complete inhibition of renal glucose reabsorption at higher doses because RTG1 values were approximately 0. Increased expression of renal SGLT1 in patients with T2DM may develop as a compensatory mechanism to increase glucose reabsorption. Indeed, SGLT1 mRNA expression is 4-fold greater in kidney biopsies of patients with T2DM compared with controls (Norton et al., 2017), suggesting that fermentation to SCFA enhances GLP-1 release in SCFA in the distal intestine (Hira et al., 2017).

We reasoned that subcutaneous administration of compound 8 might minimize the inhibition of intestinal SGLT1 during an oGTT and enable comparison of UGE at equivalent blood glucose levels. However, compound 8 given systemically not only reduced UGE after an oGTT, as expected, but also inhibited blood glucose excursion. Compound 8 was detected in the mucosa of the small intestine after systemic administration, consistent with SGLT1 engagement. Furthermore, after oral compound 8 dosing, the tissue/plasma ratio increased over time, suggesting a longer duration of action in the gut than the circulating plasma levels and terminal half-life of approximately 2 hours would indicate. Interestingly, the colonic luminal contents had increased compound 8 relative to the plasma levels 6 hours after subcutaneous dosing. This would be consistent with excretion of small intestinal brush border SGLT1-bound (or free) compound 8 from the systemic circulation that was carried by GI transit into the colon. Combined, these data suggest that compound 8 reaches the intestinal brush border rapidly after parenteral administration and inhibits SGLT1 glucose uptake for longer than the circulating half-life. SGLT1 inhibition in the small intestine is the primary mechanism for decreased blood glucose in this study; at the higher doses, glucose excursion was completely abolished, suggesting complete inhibition of uptake. In rodents, an increase in GLP-1 occurred after gut-restricted SGLT1-selective inhibitors (Powell et al., 2017) as well as diarrhea. The latter was decreased by pretreatment with resistant starch, to select for bacterial species that ferment glucose (Powell et al., 2017). Therefore, ingested glucose...
“escapes” into the large intestine, where it would be rapidly fermented as an optimal energy source for colonic bacteria. An increase in the residual glucose content has been observed in the GI tract of rats treated with the SGLT1 inhibitor KGA-2727 (Shibazaki et al., 2012) or LX4211/sotagliflozin (Powell et al., 2014). In healthy humans, it is normal for some digestible carbohydrate to reach the colon (Bond et al., 1980; Anderson et al., 1981; Stephen et al., 1983). This so-called starch malabsorption amounts to about 10%–20% of a large starch meal, based on hydrogen breath tests. Mice had similar overallecal glucose concentrations when dosed with compound 8 and fed chol or high-sucrose chol; however, we cannot rule that this was due to incomplete 24-hour SGLT1 inhibition. Cecal glucose levels were collected in the morning after overnight feeding. Interestingly, gross cecal weight was decreased in mice fed a high-sucrose diet and treated with compound 8 but cecal bacterial abundance (OTU) was not correlated with cecal glucose concentration. In mice fed a high-sucrose diet with compound 8, there were higher Bacterio- detes and lower Firmicutes represented compared with mice fed chol with compound 8 and mice fed chol plus vehicle. Because cecal and fecal microbial diversity was highly corre- lated by SDI, we compared fecal bacterial diversity during the study. Fecal SDI changed on day 2 after mice were switched to a high-sucrose diet with compound 8, but not after mice were fed compound 8 with chol. A high-sucrose diet induces obesity and changes in relative abundance of bacteria associated with metabolic disease, termed microbiota dysbiosis (e.g., Erysipe- lotrichaceae, Bifidus, Eubacterium, and Akkemansia spp.). Therefore, we conclude that increasing glucose by high- sucrose diet in the presence of compound 8 can alter microbial populations; however, compound 8 alone resulted in no overall change in glucose levels or microbial dysbiosis. This study demonstrates that a potent balanced dual SGLT1/2 inhibitor can improve glycemic control to a greater extent than SGLT1-selective compounds. This is not associated with obvious mucosal adaptation or microbial dysbiosis in these preclinical experiments. Whether this translates to sufficiently added benefit without GI adverse effects in patients with T2DM is unclear. The therapeutic margin for achieving additional glycemic benefit with a dual SGLT1/2 inhibitor compared with a potential risk for hypoglycemia due to the combined intestinal and kidney glycemic impact of SGLT1/2 inhibition is currently unknown.

Acknowledgments

The authors thank ABS Inc. and Jing Ma (Janssen, La Jolla, CA) for SGLT1 immunohistochemistry jejunal histogram and morphometric analysis and Diversigen Inc. for analysis of microbiota. We also thank Bill Kintigh, Stephen O’Sullivan, Norman Huebert, and Corey Bender (Janssen, Spring House, PA) for tissue distribution studies.

Authorship Contributions

Participated in research design: Lenhard, Demarest, Liang, Hornby.

Conducted experiments: Du, Hinke, Cavanaugh, Wallace, Kirchner, Jennis.

Performed data analysis: Du, Hinke, Cavanaugh, Polidori, Jennis, Lang, Ahami.

Wrote or contributed to the writing of the manuscript: Du, Hinke, Polidori, Hornby.

References


Downloaded from jpet.aspetjournals.org at ASPERF Journals on August 7, 2022


Sglt1 and Sglt2.


